NSAID therapeutic for cataract - SpyGlass Pharma
Latest Information Update: 21 Oct 2022
At a glance
- Originator SpyGlass Pharma
- Class Anti-inflammatories; Eye disorder therapies; Small molecules
- Mechanism of Action Inflammation mediator modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cataracts
Most Recent Events
- 19 Oct 2022 Early research in Cataracts in USA (Intraocular) prior to October 2022 (SpyGlass Pharma website, October 2022)